Acute renal toxicity associated with suramin in the treatment of prostate cancer

William D. Figg; Michael R. Cooper; Alain Thibault; Donna Headlee; Jeffrey Humphrey; Raymond C. Bergan; Eddie Reed; Oliver Sartor

doi:10.1002/1097-0142(19940901)74:5<1612::AID-CNCR2820740519>3.0.CO;2-Q

Acute renal toxicity associated with suramin in the treatment of prostate cancer

William D. Figg, Michael R. Cooper, Alain Thibault, Donna Headlee, Jeffrey Humphrey, Raymond C. Bergan, Eddie Reed, Oliver Sartor

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate cancer currently is being investigated. A 52‐year‐old man developed acute renal dysfunction after receiving nine doses of suramin. His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10.8 mg/dl during the next 6 days. The patient was not rechallenged with suramin, and his renal function returned to baseline within the next 3 weeks. Future investigators of this drug should be aware of the possibility of such a reaction with parenteral administration.

Original language	English (US)
Pages (from-to)	1612-1614
Number of pages	3
Journal	Cancer
Volume	74
Issue number	5
DOIs	https://doi.org/10.1002/1097-0142(19940901)74:5<1612::AID-CNCR2820740519>3.0.CO;2-Q
State	Published - Sep 1 1994
Externally published	Yes

Keywords

acute renal failure
nephrotoxicity
prostate cancer
renal
suramin

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(19940901)74:5<1612::AID-CNCR2820740519>3.0.CO;2-Q

Cite this

@article{b2426332e30f412f8ccd50ae9d5def94,

title = "Acute renal toxicity associated with suramin in the treatment of prostate cancer",

abstract = "The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate cancer currently is being investigated. A 52‐year‐old man developed acute renal dysfunction after receiving nine doses of suramin. His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10.8 mg/dl during the next 6 days. The patient was not rechallenged with suramin, and his renal function returned to baseline within the next 3 weeks. Future investigators of this drug should be aware of the possibility of such a reaction with parenteral administration.",

keywords = "acute renal failure, nephrotoxicity, prostate cancer, renal, suramin",

author = "Figg, {William D.} and Cooper, {Michael R.} and Alain Thibault and Donna Headlee and Jeffrey Humphrey and Bergan, {Raymond C.} and Eddie Reed and Oliver Sartor",

year = "1994",

month = sep,

day = "1",

doi = "10.1002/1097-0142(19940901)74:5<1612::AID-CNCR2820740519>3.0.CO;2-Q",

language = "English (US)",

volume = "74",

pages = "1612--1614",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Acute renal toxicity associated with suramin in the treatment of prostate cancer

AU - Figg, William D.

AU - Cooper, Michael R.

AU - Thibault, Alain

AU - Headlee, Donna

AU - Humphrey, Jeffrey

AU - Bergan, Raymond C.

AU - Reed, Eddie

AU - Sartor, Oliver

PY - 1994/9/1

Y1 - 1994/9/1

N2 - The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate cancer currently is being investigated. A 52‐year‐old man developed acute renal dysfunction after receiving nine doses of suramin. His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10.8 mg/dl during the next 6 days. The patient was not rechallenged with suramin, and his renal function returned to baseline within the next 3 weeks. Future investigators of this drug should be aware of the possibility of such a reaction with parenteral administration.

AB - The use of suramin, a polysulfonated naphthylurea, in the treatment of advanced prostate cancer currently is being investigated. A 52‐year‐old man developed acute renal dysfunction after receiving nine doses of suramin. His suramin therapy was discontinued, but his serum creatinine level continued to rise to 10.8 mg/dl during the next 6 days. The patient was not rechallenged with suramin, and his renal function returned to baseline within the next 3 weeks. Future investigators of this drug should be aware of the possibility of such a reaction with parenteral administration.

KW - acute renal failure

KW - nephrotoxicity

KW - prostate cancer

KW - renal

KW - suramin

UR - http://www.scopus.com/inward/record.url?scp=0028068481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028068481&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19940901)74:5<1612::AID-CNCR2820740519>3.0.CO;2-Q

DO - 10.1002/1097-0142(19940901)74:5<1612::AID-CNCR2820740519>3.0.CO;2-Q

M3 - Article

C2 - 8062193

AN - SCOPUS:0028068481

SN - 0008-543X

VL - 74

SP - 1612

EP - 1614

JO - Cancer

JF - Cancer

IS - 5

ER -

Acute renal toxicity associated with suramin in the treatment of prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this